ExAmp

Recently exposed flaws in Illumina, Inc. (NASDAQ: ILMN)’s gene sequencing technology, which jeopardize past medical achievements and delay progress, sent the company’s stock plunging 2 percent Friday. Cross-contamination has allegedly skewed the results of numerous sequencing endeavors...